taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs
About this study
The main objective of the REACTIVATE study is to investigate whether a period of intensive insulin therapy using closed-loop technology, when combined with diet and lifestyle education, can restore beta-cell function and achieve remission of recent-onset type 2 diabetes. This is a single-centre, open-label, randomised, parallel design study comparing up to 12 weeks of fully closed-loop insulin delivery to standard care with a glucose sensor in adults with recent-onset type 2 diabetes. The primary outcome is the number of participants achieving remission of diabetes at 52 weeks, defined as HbA1c below 48mmol/mol after 12 or more weeks off all diabetes medications. Other key outcomes include area under the curve for C-peptide and glucose during mixed meal tolerance test, the proportion of time spent with glucose levels within and above the target glucose range and mean sensor glucose as recorded by glucose sensor at 52 weeks. Safety evaluation comprises severe hypoglycaemic episodes, and other adverse and serious adverse events. Utility and human factors outcomes include glucose sensor and closed-loop usage, questionnaires and semi-structured interviews.
- Condition
- Type 2 Diabetes
- Tested
- Fully automated insulin delivery with CamAPS HX, Standard diabetes therapy with a glucose sensor
- Sponsor
- University of Cambridge
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Study condition: Type 2 Diabetes
- Aged 18 years and older
- Type 2 diabetes diagnosed \>6 months and ≤5 years ago
- Treatment with glucose lowering medication for at least 3 months
- HbA1c \>48 mmol/mol on analysis from local laboratory or equivalent
- Willing to wear study devices and follow study instructions
- Capacity to consent to participate in the study
Exclusion 11
- Type 1 diabetes
- Current use of insulin pump
- Current use of any closed-loop system
- Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician
- Known or suspected allergy against insulin
- Pregnancy, planned pregnancy, or breast feeding
- Severe visual or hearing impairment
- Medically documented allergy towards the adhesive of plasters
- Serious skin diseases located at places of the body potentially used for localisation of the glucose sensor
- Drug or alcohol misuse
- Group 2 driving licence holder
Where
1 site, 1 recruiting
Addenbrooke's Hospital NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom
Contact
-
Charlotte K Boughton
+44 (0)1223 769066 cb2000@cam.ac.uk
Potential match only. Final eligibility is determined by the study team.